Canada Life’s KalVista Pharmaceuticals KALV Stock Holding History

Canada Life’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,674	Closed	-$59K	–	1707
2019 Q2	$59K	Buy	+2,674	New	+$62.7K	﹤0.01%	2396

Other funds holding KALV

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Life's KALV Position: Q3 2019 in Review

Canada Life sold out of KalVista Pharmaceuticals (KALV) in Q3 2019, closing a stake of 2,674 shares — an estimated $59K sold.

Canada Life first reported a position in KALV in Q2 2019 and held it in 1 quarter. The position peaked at $59K in Q2 2019. 76 funds tracked by Wall St. Rank hold KALV as of Q3 2019.

Canada Life reported no remaining KalVista Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Canada Life sold 2,674 KalVista Pharmaceuticals shares in Q3 2019, an estimated $59K.
Canada Life first reported a position in KalVista Pharmaceuticals in Q2 2019 and held it in 1 quarter.
Canada Life's KalVista Pharmaceuticals position peaked at $59K in Q2 2019.
76 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2019.

Based on Canada Life's 13F filing for Q3 2019, filed 25 Oct 2019.